Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Novel series of heterocyclic compounds which have been tested and screened for growth inhibitory activity (IC50) against the K562 human chronic myelogenous leukemia cell-line using the MTT assay and for their ability to inhibit the tubulin assembly. More
Opticin has been found to exhibit anti-angiogenic (blood vessel formation) effects on a range of cell lines from different cancers More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 534 pages - $1,495
Nov 2009 - $15,200
Dec 2010 - 19 pages - $99
Nov 2010 - 40 pages - $500
Jul 2011 - 110 pages - $500
Dec 2010 - 24 pages - $500
Dec 2010 - 27 pages - $500
Jun 2006 - 1934 pages - $2,495
Mar 2011 - 21 pages - $500
Dec 2010 - 22 pages - $500
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us